Effects of Metformin on Body Weight and Body Composition in Obese Insulin-Resistant Children
Open Access
- 21 January 2011
- journal article
- research article
- Published by American Diabetes Association in Diabetes
- Vol. 60 (2) , 477-485
Abstract
OBJECTIVE: Metformin can decrease adiposity and ameliorate obesity-related comorbid conditions, including abnormalities in glucose homeostasis in adolescents, but there are few data evaluating the efficacy of metformin among younger children. Our objective was to determine whether metformin treatment causes weight loss and improves obesity-related comorbidities in obese children, who are insulin-resistant. RESEARCH DESIGN AND METHODS: This study was a randomized double-blind placebo-controlled trial consisting of 100 severely obese (mean BMI 34.6 ± 6.6 kg/m2) insulin-resistant children aged 6–12 years, randomized to 1,000 mg metformin (n = 53) or placebo (n = 47) twice daily for 6 months, followed by open-label metformin treatment for 6 months. All children and their parents participated in a monthly dietitian-administered weight-reduction program. RESULTS: Eighty-five percent completed the 6-month randomized phase. Children prescribed metformin had significantly greater decreases in BMI (difference −1.09 kg/m2, CI −1.87 to −0.31, P = 0.006), body weight (difference −3.38 kg, CI −5.2 to −1.57, P < 0.001), BMI Z score (difference between metformin and placebo groups −0.07, CI −0.12 to −0.01, P = 0.02), and fat mass (difference −1.40 kg, CI −2.74 to −0.06, P = 0.04). Fasting plasma glucose (P = 0.007) and homeostasis model assessment (HOMA) insulin resistance index (P = 0.006) also improved more in metformin-treated children than in placebo-treated children. Gastrointestinal symptoms were significantly more prevalent in metformin-treated children, which limited maximal tolerated dosage in 17%. During the 6-month open-label phase, children treated previously with placebo decreased their BMI Z score; those treated continuously with metformin did not significantly change BMI Z score further. CONCLUSIONS: Metformin had modest but favorable effects on body weight, body composition, and glucose homeostasis in obese insulin-resistant children participating in a low-intensity weight-reduction program.Keywords
This publication has 52 references indexed in Scilit:
- Metformin Extended Release Treatment of Adolescent ObesityArchives of Pediatrics & Adolescent Medicine, 2010
- The Stability of Metabolic Syndrome in Children and AdolescentsThe Journal of Clinical Endocrinology & Metabolism, 2009
- Family-Based Treatment of Severe Pediatric Obesity: Randomized, Controlled TrialPediatrics, 2009
- Metformin for Obesity in Children and Adolescents: A Systematic ReviewDiabetes Care, 2009
- Addition of Metformin to a Lifestyle Modification Program in Adolescents with Insulin ResistanceThe Journal of Pediatrics, 2008
- Insulin Resistance, Hyperinsulinemia, and Energy Intake in Overweight ChildrenThe Journal of Pediatrics, 2008
- Childhood Obesity Predicts Adult Metabolic Syndrome: The Fels Longitudinal StudyThe Journal of Pediatrics, 2008
- Insulin Dynamics Predict Body Mass Index and Z-Score Response to Insulin Suppression or Sensitization Pharmacotherapy in Obese ChildrenThe Journal of Pediatrics, 2006
- Relative role of major risk factors for Type 2 diabetes development in the historical cohort of the Brisighella Heart Study: an 8‐year follow‐upDiabetic Medicine, 2005
- Do Children Lose and Maintain Weight Easier Than Adults: A Comparison of Child and Parent Weight Changes From Six Months to Ten YearsObesity Research, 1995